Healthcare Industry News: endoluminal stent graft
News Release - October 3, 2007
Endologix Announces Successful Powerlink Deployments with Advanced Visiflex Integrated System
IRVINE, Calif.--(HSMN NewsFeed)--Endologix, Inc. (Nasdaq:ELGX ) today announced the first seven Powerlink® System procedures for the minimally invasive treatment of abdominal aortic aneurysms (AAA) have been successfully performed using the Company's advanced Visiflex Integrated System, or Visiflex IS.The Visiflex IS, Endologix's third-generation delivery system, is designed to simplify the endoluminal stent graft (ELG) deployment and catheter withdrawal by eliminating the front sheath that currently deploys the main body of the Powerlink System. The single sheath design makes insertion through challenging iliac anatomy easier giving physicians confidence to treat a broader spectrum of patients. The Visiflex IS permits the operator to utilize the Powerlink System's outer sleeve as a 19 french hemostatic introducer sheath. This outer sleeve acts as a conduit for adjunctive procedures and eliminates catheter exchanges.
Of the first seven procedures using the Visiflex IS, one was performed at the Southern Clinic in Nuremberg, Germany, one at the Imelda Hospital in Bonheiden, Belgium, three at St. Joseph Hospital in Marseille, France, and two at the Wilhelminenspital in Vienna, Austria.
- Professor Dieter Raithel, M.D., Southern Clinic, stated, "Having performed more than 480 successful Powerlink System implants, I believe the Visiflex IS will simplify the access in extremely tortuous and calcified vessels."
- Patrick Peeters, M.D., Imelda Hospital, stated, "The new Visiflex IS delivery system has qualities comparable to a standard introducer sheath, allowing me to position the ELG device even in those patients with tortuous and compromised access vessels."
- Patrice Bergeron, M.D., St. Joseph Hospital, stated, "The Visiflex IS' built-in introducer sleeve represents a significant improvement by facilitating a truly minimally invasive stent graft delivery."
"Endologix is again leading the development of innovative minimally invasive technology for the treatment of AAA," said Paul McCormick, president and CEO of Endologix. "We believe the Powerlink System is very well positioned given our first-in-class long-term clinical results and our ability to stay at the cutting edge of innovation."
The Powerlink with Visiflex IS has received CE Mark for distribution in the European Union. The Visiflex IS is not approved for sale in the United States.
About Endologix
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements, including those related to the expected advantages of the Visiflex IS design, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's other filings with the Securities and Exchange Commission for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
Source: Endologix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
